NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 102.39

Change

+4.64 (+4.75)%

Market Cap

USD 0.67B

Volume

1.37M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 38.79B
ICLR ICON PLC

N/A

USD 25.88B
ILMN Illumina Inc

N/A

USD 20.48B
EXAS EXACT Sciences Corporation

N/A

USD 11.40B
MEDP Medpace Holdings Inc

N/A

USD 10.76B
RDNT RadNet Inc

N/A

USD 4.64B
SHC Sotera Health Co

N/A

USD 4.37B
NEOG Neogen Corporation

N/A

USD 3.49B
GH Guardant Health Inc

N/A

USD 3.00B
MYGN Myriad Genetics Inc

N/A

USD 2.49B

ETFs Containing NTRA

EKG First Trust Nasdaq Lux Di.. 5.29 % 0.00 %

N/A

USD 2.52M
CURG:LSE VanEck Genomics and Healt.. 4.75 % 0.00 %

N/A

USD 6.97M
GNOM Global X Genomics & Biote.. 4.67 % 0.00 %

N/A

USD 0.09B
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 4.42 % 0.00 %

N/A

USD 6.11M
GN0M:XETRA Global X Genomics & Biote.. 3.84 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.84 % 0.00 %

N/A

USD 5.87M
PTH Invesco DWA Healthcare Mo.. 3.00 % 0.60 %

N/A

USD 0.14B
WBIO:LSE WisdomTree BioRevolution .. 2.58 % 0.00 %

N/A

USD 3.68M
WDNA 2.51 % 0.00 %

N/A

N/A
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.27 % 0.00 %

N/A

USD 2.77M
DOCG:LSE L&G Healthcare Breakthrou.. 1.78 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.78 % 0.00 %

N/A

USD 0.07B
ZUH:CA BMO Equal Weight US Healt.. 1.67 % 0.39 %

N/A

CAD 0.28B
SCHA Schwab U.S. Small-Cap ETF 0.37 % 0.05 %

N/A

USD 17.78B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.30B
BTEC 0.00 % 0.42 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

N/A
IS0R:XETRA iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

USD 2.71B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

N/A

USD 0.05B
ATFV Alger 35 ETF 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 63.46% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.46% 92% A 93% A
Trailing 12 Months  
Capital Gain 133.08% 98% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 133.08% 98% N/A 97% N/A
Trailing 5 Years  
Capital Gain 269.77% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 269.77% 93% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 46.62% 84% B 90% A-
Dividend Return 46.62% 84% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.31% 31% F 18% F
Risk Adjusted Return 52.79% 88% B+ 80% B-
Market Capitalization 0.67B 91% A- 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 14.90 10% 7%
Price / Cash Flow Ratio -52.70 98% 95%
Price/Free Cash Flow Ratio -27.58 93% 92%
Management Effectiveness  
Return on Equity -50.59% 50% 31%
Return on Invested Capital -40.41% 48% 25%
Return on Assets -17.14% 46% 27%
Debt to Equity Ratio 36.97% 55% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector